Validation of an artificial intelligence-based automated PRAGMA and mucus plugging algorithm in pediatric cystic fibrosisLan Mi2025-08-24T11:54:47+00:00
Elexacaftor/tezacafor/ivacaftor improves bronchial dilatation in a real-world cohort of adolescents with cystic fibrosisLan Mi2025-08-05T14:32:28+00:00
Measuring segmental lung changes of Cystic Fibrosis patients before and after Elexacaftor-Tezacaftor-Ivacaftor (ETI) with an automated analysis methodLan Mi2025-07-31T09:03:36+00:00
Improvements in structural lung disease in people with CF aged 12 and above on Elexacaftor/Tezacaftor/Ivacaftor (ETI) are sustained for up to two yearsLan Mi2025-07-31T09:04:40+00:00
Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real-Life StudyLan Mi2025-06-05T12:16:52+00:00
Fully Automatic Assessment of Bronchus-Artery Dimensions and Ratios, Mucus Plugs, and Low Attenuation Regions in Cystic Fibrosis Patients Before and After Elexacaftor-Tezacaftor-Ivacaftoradmin2024-05-29T11:18:43+00:00
The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world settingadmin2023-10-23T11:24:52+00:00
Automatic Bronchus and Artery Analysis on Chest Computed Tomography to Evaluate the Effect of Inhaled Hypertonic Saline in Children Aged 3-6 Years With Cystic Fibrosis in a Randomized Clinical Trialadmin2023-10-23T11:24:56+00:00
